arrow
Y

Yasmin Nabil Laimon

Brigham and Women's Hospital
H指数:7
被引数:228

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma

融合驱动致癌程序塑造重排型肾细胞癌的免疫景观

2026-08-260
OA
fusion derived oncogenic programs shape the immune landscape in translocation renal cell carcinoma

融合衍生致癌程序塑造易位性肾细胞癌的免疫景观

2025-10-010
OAAI
Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity

Cyclin A/B RxL 环状大环抑制剂用于治疗高 E2F 活性癌症

2025-08-290
PRE
The Polycomb Protein EED Constrains the SCLC Neuroendocrine Phenotype and Drives Lung Cancer Histological Transformation

多梳蛋白EED限制小细胞肺癌神经内分泌表型并驱动肺癌组织学转化

2025-08-290
PRE
Loss of NOTCH2 creates a TRIM28-dependent vulnerability in small cell lung cancer

NOTCH2的缺失在小型细胞肺癌中引发了一种TRIM28依赖性的易感性。

2025-08-260
PRE
Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors

靶向G1-S检验点受损的癌症,使用细胞周期蛋白A/B RxL抑制剂

Nature
IF48.5
2025-08-200
OA
Tertiary Lymphoid Structures Predict Response to First-Line Nivolumab Therapy in Advanced Renal Cell Carcinoma: Findings from the HCRN GU16-260 Clinical Trial

三级淋巴结构预测晚期肾细胞癌一线Nivolumab治疗的反应: HCRN GU16-260临床试验的结果

2025-03-010
PRE
Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma

肉瘤样分化的表观基因组特征指导肾细胞癌的治疗

2024-06-010
OA
Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects

亲和力微调抗CAIX car-t细胞减轻中靶肿瘤外副作用

2024-03-164
OAAI
Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma

转移性透明细胞肾细胞癌对免疫检查点抑制异常反应的决定因素

2023-10-010
OAAI
KDM6A epigenetically regulates subtype plasticity in small cell lung cancer

KDM6A表观遗传调控小细胞肺癌亚型可塑性

2023-08-1717
PRE
Epigenomic profiling nominates master transcription factors (TFs) driving sarcomatoid differentiation of renal cell carcinoma (RCC)

表观基因组分析提名主转录因子 (TFs) 驱动肾细胞癌 (RCC) 的肉瘤样分化

2023-08-150
PRE
Small cell lung cancer subtype plasticity is regulated by KDM6A
2023-04-041
PRE
Fine-tuned CAIX targeted CAR-T cells exhibit superior efficacy and mitigate ontarget off-tumor side effects
2023-04-041
PRE